From Conventional to Novel Drug Delivery Systems for Meloxicam: A Systematic Review

IF 3 4区医学 Q2 PHARMACOLOGY & PHARMACY Critical Reviews in Therapeutic Drug Carrier Systems Pub Date : 2024-02-01 DOI:10.1615/critrevtherdrugcarriersyst.2024048988

Manjusha Annaji, Nur Mita, Jessica Heard, Xuejia Kang, Ishwor Poudel, Sai H.S. Boddu, Amit K. Tiwari, R. Jayachandra Babu

{"title":"From Conventional to Novel Drug Delivery Systems for Meloxicam: A Systematic Review","authors":"Manjusha Annaji, Nur Mita, Jessica Heard, Xuejia Kang, Ishwor Poudel, Sai H.S. Boddu, Amit K. Tiwari, R. Jayachandra Babu","doi":"10.1615/critrevtherdrugcarriersyst.2024048988","DOIUrl":null,"url":null,"abstract":"Meloxicam, a selective COX-2 inhibitor, has demonstrated clinical effectiveness in managing inflammation and acute pain. Although available in oral formulations such as capsules, tablets, and suspension, frequent administration is necessary to maintain therapeutic efficacy, which can increase adverse effects and patient non-compliance. To address these issues, several sustained drug delivery strategies such as oral, transdermal, transmucosal, injectable, implantable drug delivery systems have been developed for meloxicam. These sustained drug delivery strategies have the potential to improve the therapeutic efficacy and safety profile of meloxicam by reducing the frequency of dosing and associated gastrointestinal side effects. The choice of drug delivery system will depend on the desired release profile, the target site of inflammation, and the mode of administration. Overall, meloxicam sustained delivery systems offer better patient compliance, and reduce side effects, thereby improving the clinical applications of this drug. Herein, we discuss in detail the different strategies for the sustained delivery of meloxicam.","PeriodicalId":50614,"journal":{"name":"Critical Reviews in Therapeutic Drug Carrier Systems","volume":"16 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Therapeutic Drug Carrier Systems","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1615/critrevtherdrugcarriersyst.2024048988","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Meloxicam, a selective COX-2 inhibitor, has demonstrated clinical effectiveness in managing inflammation and acute pain. Although available in oral formulations such as capsules, tablets, and suspension, frequent administration is necessary to maintain therapeutic efficacy, which can increase adverse effects and patient non-compliance. To address these issues, several sustained drug delivery strategies such as oral, transdermal, transmucosal, injectable, implantable drug delivery systems have been developed for meloxicam. These sustained drug delivery strategies have the potential to improve the therapeutic efficacy and safety profile of meloxicam by reducing the frequency of dosing and associated gastrointestinal side effects. The choice of drug delivery system will depend on the desired release profile, the target site of inflammation, and the mode of administration. Overall, meloxicam sustained delivery systems offer better patient compliance, and reduce side effects, thereby improving the clinical applications of this drug. Herein, we discuss in detail the different strategies for the sustained delivery of meloxicam.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

美洛昔康的传统给药系统到新型给药系统：系统综述

美洛昔康是一种选择性 COX-2 抑制剂，在治疗炎症和急性疼痛方面具有显著的临床疗效。虽然美洛昔康有胶囊、片剂和混悬剂等口服制剂，但必须频繁给药才能维持疗效，这可能会增加不良反应和患者的不依从性。为解决这些问题，美洛昔康已开发出多种持续给药策略，如口服、透皮、透粘膜、注射和植入式给药系统。这些持续给药策略有可能通过减少给药次数和相关的胃肠道副作用来提高美洛昔康的疗效和安全性。给药系统的选择取决于所需的释放曲线、目标炎症部位和给药方式。总之，美洛昔康持续给药系统能使患者更好地遵从医嘱，减少副作用，从而改善该药物的临床应用。在此，我们将详细讨论美洛昔康持续给药的不同策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Critical Reviews in Therapeutic Drug Carrier Systems 医学-药学

CiteScore

5.50

自引率

18.50%

发文量

审稿时长

>12 weeks

期刊介绍： Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields. Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.